Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis

World Journal of Gastroenterology

Volumn 18, Issue 9, 2012, Pages 872-881

  Vilela, Eduardo Garcia ^a   da Gama Torres, Henrique Osvaldo ^a   Martin, Fabiana Paiva ^a   de Lourdes de Abreu Ferrari, Maria ^a   Andrade, Marcella Menezes ^a   da Cunha, Aloísio Sales ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Crohn's disease; Diagnostic test; Inflammatory bowel disease; Inflammatory markers; Therapy; Ulcerative colitis

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 GLOBULIN; AZATHIOPRINE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; ELASTASE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILIC PROTEIN X; FIBRINOGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 6; LACTOFERRIN; LYSOZYME; MERCAPTOPURINE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OROSOMUCOID; POLYMORPHONUCLEAR ELASTASE; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ABDOMINAL RADIOGRAPHY; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTED TOMOGRAPHY ENTEROGRAPHY; COMPUTER ASSISTED DIAGNOSIS; CONCENTRATION (PARAMETERS); CROHN DISEASE; CYTOKINE PRODUCTION; DEGRANULATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; INFLAMMATION; LEUKOCYTE DEGRANULATION; LEUKOCYTOSIS; MAGNETIC RESONANCE ENTEROGRAPHY; MALABSORPTION; MALNUTRITION; OCCULT BLOOD; PHAGOCYTE; POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; SCORING SYSTEM; SEROLOGY; STOMACH MUCOSA INJURY; THROMBOCYTOSIS; ULCERATIVE COLITIS;

EID: 84858022525     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i9.872     Document Type: Article

References (115)

1. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442; quiz 464
2. Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Heimann T, Janowitz HD, Aufses AH Jr. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988; 29: 588-592
3. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260
5. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
6. de Dombal FT, Softley A. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987; 28: 474-481
7. van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279-286
8. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity-the Cape Town index. S Afr Med J 1985; 68: 502-503
9. Myren J, Bouchier IA, Watkinson G, Softley A, Clamp SE, de Dombal FT. The O.M.G.E. Multinational Inflammatory Bowel Disease Survey 1976-1982. A further report on 2,657 cases. Scand J Gastroenterol Suppl 1984; 95: 1-27
10. Talstad I, Gjone E. The disease activity of ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1976; 11: 403-408
11. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Gooclinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810
12. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048
13. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-837
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-86
15. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-1197
16. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-19
17. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-431
18. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58: 859-868
19. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-169
20. Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-519
21. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 809-813
22. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-712
23. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD, Stevens AC. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20
24. Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001; 46: 644-648
25. Dearing WH, McGuckin WF, Elveback LR. Serum 1-acid glycoprotein in chronic ulcerative colitis. Gastroenterology 1969; 56: 295-303
26. Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986; 8: 647-650
27. Sachar DB, Luppescu NE, Bodian C, Shlien RD, Fabry TL, Gumaste VV. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990; 12: 643-646
28. Jensen KB, Jarnum S, Koudahl G, Kristensen M. Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976; 11: 177-183
29. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359-367
30. Brimnes J, Nielsen OH, Wiik A, Heegaard NH. Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis. Dig Dis Sci 1999; 44: 415-423
31. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100: 1590-1596
32. Sobajima J, Ozaki S, Uesugi H, Osakada F, Shirakawa H, Yoshida M, Nakao K. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol 1998; 111: 402-407
33. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791
34. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996; 110: 1810-1819
35. Malickova K, Lakatos PL, Bortlik M, Komarek V, Janatkova I, Lukas M. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. Eur J Gastroenterol Hepatol 2010; 22: 144-150
36. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J, Rogler G, Dotan N, Klebl F. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010; 16: 1367-1375
37. Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci 2008; 53: 242-247
38. Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, Matsumoto K. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study. Inflamm Bowel Dis 2007; 13: 1493-1501
39. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis 2005; 11: 589-596
40. Spoettl T, Hausmann M, Klebl F, Dirmeier A, Klump B, Hoffmann J, Herfarth H, Timmer A, Rogler G. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis 2007; 13: 727-732
41. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32: 1531-1534
42. Mitsuyama K, Tomiyasu N, Takaki K, Masuda J, Yamasaki H, Kuwaki K, Takeda T, Kitazaki S, Tsuruta O, Sata M. Interleukin- 10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm 2006; 2006: 26875
43. Ljuca F, Gegic A, Salkic NN, Pavlovic-Calic N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Dig Dis Sci 2010; 55: 2316-2326
44. Saitoh O, Matsumoto H, Sugimori K, Sugi K, Nakagawa K, Miyoshi H, Hirata I, Matsuse R, Uchida K, Ohshiba S. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and α-1-antitrypsin levels in patients with colorectal diseases. Digestion 1995; 56: 67-75
45. Fischbach W, Becker W, Mössner J, Koch W, Reiners C. Faecal α-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987; 28: 386-393
46. Saverymuttu SH, Peters AM, Hodgson HJ, Chadwick VS. Assessment of disease activity in ulcerative colitis using indium-111-labelled leukocyte faecal excretion. Scand J Gastroenterol 1983; 18: 907-912
47. Røseth AG, Schmidt PN, Fagerhol MK. Correlation betweenfaecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-54
48. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7: 460-465
49. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 1755-1762
50. Bischoff SC, Mayer J, Nguyen QT, Stolte M, Manns MP. Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3521-3529
51. Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, Nakagawa K, Kayazawa M, Hirata I, Katsu K. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3513-3520
52. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37
53. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-853
54. Roth J, Vogl T, Sorg C, Sunderkötter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003; 24: 155-158
55. Brinar M, Cleynen I, Coopmans T, Van Assche G, Rutgeerts P, Vermeire S. Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity. Gut 2010; 59: 1728-1729; author reply 1729-1730
56. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-α therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-1398
57. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22
58. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368
59. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-2014
60. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369
61. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci (Lond) 1992; 82: 471-488
62. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinalpermeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341: 1437-1439
63. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000; 35: 1163-1169
64. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-989
65. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-1653
66. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-512
67. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
68. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868
69. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
70. Baron JH, Connell AM, Lennard-jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89-92
71. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629
72. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-1898
73. Hirai F, Matsui T, Aoyagi K, Inoue N, Hibi T, Oshitani N, Fujii H, Kobayashi K, Suzuki Y, Tanaka S. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc 2010; 22: 39-44
74. Osada T, Ohkusa T, Yokoyama T, Shibuya T, Sakamoto N, Beppu K, Nagahara A, Otaka M, Ogihara T, Watanabe S. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis 2010; 16: 192-197
75. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786
76. Dietrich CF. Significance of abdominal ultrasound in inflammatory bowel disease. Dig Dis 2009; 27: 482-493
77. Migaleddu V, Quaia E, Scano D, Virgilio G. Inflammatory activity in Crohn disease: ultrasound findings. Abdom Imaging 2008; 33: 589-597
78. Maconi G, Radice E, Greco S, Bianchi Porro G. Bowel ultrasound in Crohn's disease. Best Pract Res Clin Gastroenterol 2006; 20: 93-112
79. Maconi G, Parente F, Bollani S, Cesana B, Bianchi Porro G. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol 1996; 91: 1604-1609
80. Fraquelli M, Colli A, Casazza G, Paggi S, Colucci A, Massironi S, Duca P, Conte D. Role of US in detection of Crohn disease: meta-analysis. Radiology 2005; 236: 95-101
81. Hata J, Haruma K, Suenaga K, Yoshihara M, Yamamoto G, Tanaka S, Shimamoto T, Sumii K, Kajiyama G. Ultrasonographic assessment of inflammatory bowel disease. Am J Gastroenterol 1992; 87: 443-447
82. Maconi G, Parente F, Bollani S, Imbesi V, Ardizzone S, Russo A, Bianchi Porro G. Factors affecting splanchnic haemodynamics in Crohn's disease: a prospective controlled study using Doppler ultrasound. Gut 1998; 43: 645-650
83. van Oostayen JA, Wasser MN, van Hogezand RA, Griffioen G, de Roos A. Activity of Crohn disease assessed by measurement of superior mesenteric artery flow with Doppler US. Radiology 1994; 193: 551-554
84. van Oostayen JA, Wasser MN, van Hogezand RA, Griffioen G, Biemond I, Lamers CB, de Roos A. Doppler sonography evaluation of superior mesenteric artery flow to assess Crohn's disease activity: correlation with clinical evaluation, Crohn's disease activity index, and α 1-antitrypsin clearance in feces. AJR Am J Roentgenol 1997; 168: 429-433
85. van Oostayen JA, Wasser MN, Griffioen G, van Hogezand RA, Lamers CB, de Roos A. Activity of Crohn's disease assessedby measurement of superior mesenteric artery flow with Doppler ultrasound. Neth J Med 1998; 53: S3-S8
86. van Oostayen JA, Wasser MN, Griffioen G, van Hogezand RA, Lamers CB, de Roos A. Diagnosis of Crohn's ileitis and monitoring of disease activity: value of Doppler ultrasound of superior mesenteric artery flow. Am J Gastroenterol 1998; 93: 88-91
87. Erden A, Cumhur T, Olçer T. Superior mesenteric artery Doppler waveform changes in response to inflammation of the ileocecal region. Abdom Imaging 1997; 22: 483-486
88. Byrne MF, Farrell MA, Abass S, Fitzgerald A, Varghese JC, Thornton F, Murray FE, Lee MJ. Assessment of Crohn's disease activity by Doppler sonography of the superior mesenteric artery, clinical evaluation and the Crohn's disease activity index: a prospective study. Clin Radiol 2001; 56: 973-978
89. Sjekavica I, Barbarić-Babić V, Krznarić Z, Molnar M, Cuković-Cavka S, Stern-Padovan R. Assessment of Crohn's disease activity by doppler ultrasound of superior mesenteric artery and mural arteries in thickened bowel wall: cross-sectional study. Croat Med J 2007; 48: 822-830
90. Neye H, Voderholzer W, Rickes S, Weber J, Wermke W, Lochs H. Evaluation of criteria for the activity of Crohn's disease by power Doppler sonography. Dig Dis 2004; 22: 67-72
91. Spalinger J, Patriquin H, Miron MC, Marx G, Herzog D, Dubois J, Dubinsky M, Seidman EG. Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology 2000; 217: 787-791
92. Kratzer W, Schmidt SA, Mittrach C, Haenle MM, Mason RA, Von Tirpitz C, Pauls S. Contrast-enhanced wideband harmonic imaging ultrasound (SonoVue): a new technique for quantifying bowel wall vascularity in Crohn's disease. Scand J Gastroenterol 2005; 40: 985-991
93. Rapaccini GL, Pompili M, Orefice R, Covino M, Riccardi L, Cedrone A, Gasbarrini G. Contrast-enhanced power doppler of the intestinal wall in the evaluation of patients with Crohn disease. Scand J Gastroenterol 2004; 39: 188-194
94. Robotti D, Cammarota T, Debani P, Sarno A, Astegiano M. Activity of Crohn disease: value of Color-Power-Doppler and contrast-enhanced ultrasonography. Abdom Imaging 2004; 29: 648-652
95. Migaleddu V, Scanu AM, Quaia E, Rocca PC, Dore MP, Scanu D, Azzali L, Virgilio G. Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. Gastroenterology 2009; 137: 43-52
96. Braden B, Ignee A, Hocke M, Palmer RM, Dietrich C. Diagnostic value and clinical utility of contrast enhanced ultrasound in intestinal diseases. Dig Liver Dis 2010; 42: 667-674
97. Kratzer W, von Tirpitz C, Mason R, Reinshagen M, Adler G, Möller P, Rieber A, Kächele V. Contrast-enhanced power Doppler sonography of the intestinal wall in the differentiation of hypervascularized and hypovascularized intestinal obstructions in patients with Crohn's disease. J Ultrasound Med 2002; 21: 149-157; quiz 158-159
98. Ludwig D, Wiener S, Brüning A, Schwarting K, Jantschek G, Fellermann K, Stahl M, Stange EF. Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study. Gut 1999; 45: 546-552
99. Tochetto S, Yaghmai V. CT enterography: concept, technique, and interpretation. Radiol Clin North Am 2009; 47: 117-132
100. Huprich JE, Fletcher JG. CT enterography: principles, technique and utility in Crohn's disease. Eur J Radiol 2009; 69: 393-397
101. Paulsen SR, Huprich JE, Fletcher JG, Booya F, Young BM, Fidler JL, Johnson CD, Barlow JM, Earnest F 4th. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics 2006; 26: 641-657; discussion 657-662
102. Madureira AJ. The comb sign. Radiology 2004; 230: 783-784
103. Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn WJ, Loftus EV Jr, Harmsen WS. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 2006; 241: 787-795
104. Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV Jr, Harmsen WS, Crownhart BS. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology 2006; 238: 505-516
105. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006; 55: 1561-1567
106. Paulsen SR, Huprich JE, Hara AK. CT enterography: noninvasive evaluation of Crohn's disease and obscure gastrointestinal bleed. Radiol Clin North Am 2007; 45: 303-315
107. Guidi L, Minordi LM, Semeraro S, De Vitis I, Roberto I, Ennas S, Guglielmo S, Di Candia L, Papa A, Urgesi R, Grillo A, Brizi MG, Vecchioli A, Fedeli G. Clinical correlations of small bowel CT and contrast radiology findings in Crohn's disease. Eur Rev Med Pharmacol Sci 2004; 8: 215-217
108. Higgins PD, Caoili E, Zimmermann M, Bhuket TP, Sonda LP, Manoogian B, Platt JF, Zimmermann EM. Computed tomographic enterography adds information to clinical management in small bowel Crohn's disease. Inflamm Bowel Dis 2007; 13: 262-268
109. Jaffe TA, Gaca AM, Delaney S, Yoshizumi TT, Toncheva G, Nguyen G, Frush DP. Radiation doses from small-bowel follow- through and abdominopelvic MDCT in Crohn's disease. AJR Am J Roentgenol 2007; 189: 1015-1022
110. Tolan DJ, Greenhalgh R, Zealley IA, Halligan S, Taylor SA. MR enterographic manifestations of small bowel Crohn disease. Radiographics 2010; 30: 367-384
111. Siddiki H, Fidler J. MR imaging of the small bowel in Crohn's disease. Eur J Radiol 2009; 69: 409-417
112. Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV Jr, Sandborn WJ, Pardi DS, Mandrekar JN. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193: 113-121
113. Lee SS, Kim AY, Yang SK, Chung JW, Kim SY, Park SH, Ha HK. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009; 251: 751-761
114. Giusti S, Faggioni L, Neri E, Fruzzetti E, Nardini L, Marchi S, Bartolozzi C. Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and time-signal intensity curves for differentiating between active and inactive Crohn's disease. Abdom Imaging 2010; 35: 646-653
115. Leyendecker JR, Bloomfeld RS, DiSantis DJ, Waters GS, Mott R, Bechtold RE. MR enterography in the management of patients with Crohn disease. Radiographics 2009; 29: 1827-1846